MX361873B - Formulaciones de opioides. - Google Patents
Formulaciones de opioides.Info
- Publication number
- MX361873B MX361873B MX2015001033A MX2015001033A MX361873B MX 361873 B MX361873 B MX 361873B MX 2015001033 A MX2015001033 A MX 2015001033A MX 2015001033 A MX2015001033 A MX 2015001033A MX 361873 B MX361873 B MX 361873B
- Authority
- MX
- Mexico
- Prior art keywords
- buprenorphine
- opioid formulations
- methods
- depot
- opioid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 2
- 229960001736 buprenorphine Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
Abstract
Una formulación precursora de depósito que comprende: a) una matriz de liberación controlada; b) al menos solvente orgánico que contiene oxígeno; c) al menos 12 % en peso de al menos un agente activo que se selecciona de la buprenorfina y sales de esta, calculada como base libre de buprenorfina. Se proporcionan composiciones de depósito y métodos de tratamiento correspondientes en cuanto al manejo del dolor mediante mantenimiento con opioides y métodos relacionados.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/558,463 US20130190341A1 (en) | 2004-06-04 | 2012-07-26 | High bioavailability opioid formulations |
| US201361806185P | 2013-03-28 | 2013-03-28 | |
| PCT/EP2013/065855 WO2014016428A1 (en) | 2012-07-26 | 2013-07-26 | Opioid formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015001033A MX2015001033A (es) | 2015-04-09 |
| MX361873B true MX361873B (es) | 2018-12-18 |
Family
ID=53487482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015001033A MX361873B (es) | 2012-07-26 | 2013-07-26 | Formulaciones de opioides. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20240075024A1 (es) |
| JP (1) | JP6417327B2 (es) |
| CN (1) | CN109010255B (es) |
| AU (3) | AU2016244271B2 (es) |
| CL (1) | CL2015000197A1 (es) |
| CY (1) | CY1124016T1 (es) |
| DK (1) | DK2877155T3 (es) |
| EA (1) | EA034855B1 (es) |
| ES (1) | ES2837803T3 (es) |
| HK (2) | HK1205948A1 (es) |
| HR (1) | HRP20210068T1 (es) |
| HU (1) | HUE053273T2 (es) |
| IL (3) | IL296882A (es) |
| LT (1) | LT2877155T (es) |
| MX (1) | MX361873B (es) |
| MY (1) | MY189481A (es) |
| NZ (2) | NZ704012A (es) |
| PE (1) | PE20150672A1 (es) |
| PT (1) | PT2877155T (es) |
| SG (2) | SG11201500554XA (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| EP3691618A1 (en) * | 2017-10-06 | 2020-08-12 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
| WO2020240018A1 (en) * | 2019-05-29 | 2020-12-03 | Camurus Ab | Administration device & regime |
| WO2023020608A1 (zh) * | 2021-08-20 | 2023-02-23 | 苏州恩华生物医药科技有限公司 | 一种包含塞纳布啡的药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| AU2005249274B2 (en) * | 2004-06-04 | 2011-02-24 | Camurus Ab | Liquid depot formulations |
| ATE462409T1 (de) * | 2005-01-14 | 2010-04-15 | Camurus Ab | Topische bioadhäsive formulierungen |
| PL1848403T3 (pl) * | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
| US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| GB2481018B (en) * | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
-
2013
- 2013-07-26 MX MX2015001033A patent/MX361873B/es active IP Right Grant
- 2013-07-26 MY MYPI2015000187A patent/MY189481A/en unknown
- 2013-07-26 JP JP2015523571A patent/JP6417327B2/ja active Active
- 2013-07-26 IL IL296882A patent/IL296882A/en unknown
- 2013-07-26 EA EA201590202A patent/EA034855B1/ru unknown
- 2013-07-26 PE PE2015000092A patent/PE20150672A1/es active IP Right Grant
- 2013-07-26 LT LTEP13744494.9T patent/LT2877155T/lt unknown
- 2013-07-26 DK DK13744494.9T patent/DK2877155T3/da active
- 2013-07-26 ES ES13744494T patent/ES2837803T3/es active Active
- 2013-07-26 SG SG11201500554XA patent/SG11201500554XA/en unknown
- 2013-07-26 CN CN201810814126.0A patent/CN109010255B/zh active Active
- 2013-07-26 NZ NZ704012A patent/NZ704012A/en unknown
- 2013-07-26 SG SG10201703964TA patent/SG10201703964TA/en unknown
- 2013-07-26 NZ NZ735248A patent/NZ735248A/en unknown
- 2013-07-26 HU HUE13744494A patent/HUE053273T2/hu unknown
- 2013-07-26 PT PT137444949T patent/PT2877155T/pt unknown
-
2015
- 2015-01-18 IL IL236762A patent/IL236762A0/en active IP Right Grant
- 2015-01-26 CL CL2015000197A patent/CL2015000197A1/es unknown
- 2015-07-10 HK HK15106598.6A patent/HK1205948A1/xx unknown
-
2016
- 2016-08-05 HK HK16109379.4A patent/HK1221636A1/zh unknown
- 2016-10-13 AU AU2016244271A patent/AU2016244271B2/en active Active
-
2017
- 2017-12-20 AU AU2017279657A patent/AU2017279657B2/en active Active
-
2019
- 2019-02-13 AU AU2019200982A patent/AU2019200982B2/en active Active
-
2021
- 2021-01-13 CY CY20211100023T patent/CY1124016T1/el unknown
- 2021-01-14 HR HRP20210068TT patent/HRP20210068T1/hr unknown
- 2021-12-20 IL IL289157A patent/IL289157A/en unknown
-
2023
- 2023-11-02 US US18/500,595 patent/US20240075024A1/en active Pending
- 2023-11-02 US US18/500,603 patent/US20240226091A9/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7190238A2 (es) | Formulaciones de opioides | |
| UA118182C2 (uk) | Дифторметилнікотинові інданілкарбоксаміди | |
| NZ719079A (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| TN2014000001A1 (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| NZ602111A (en) | Extended release formulations of rasagiline and uses thereof | |
| CY1124016T1 (el) | Φαρμακοτεχνικες μορφες οπιοειδων | |
| PH12015501982A1 (en) | Pharmaceutical compositions comprising everolimus | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| MY183540A (en) | Injectable buprenorphine formulation | |
| IN2014DN01619A (es) | ||
| MY196998A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| IN2015DN01329A (es) | ||
| MX357704B (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| MX2015004312A (es) | Formulacion de aroma y fragancia (i). | |
| MX359955B (es) | Formulación de aroma y fragancia (iii). | |
| MX2021013699A (es) | Formulaciones de opioides. | |
| EP2588112A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| MX360017B (es) | Formulación de aroma y fragancia (iv). | |
| MX360531B (es) | Formulación de aroma y fragancia (ii). | |
| MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| UA61103U (ru) | Фармацевтическая композиция для лечения множественно-резистентных форм туберкулеза | |
| UA69383U (ru) | Гель для обработки рук с противобактериальным действием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |